SCHEMBL20689556

SCHEMBL20689556

CCOC(=O)c1cnn2c(N(C)C(=O)OC(C)(C)C)cc(Nc3cc(C)c(=O)n(Cc4ccccc4)c3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ P2RX7 Q99572 3/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CASP1 P29466 2/20 0.39
▸ CASP7 P55210 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ P2RX3 P56373 5/20 0.36
▸ TYK2 P29597 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ERBB2 P04626 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20689558 0.83 TYK2 (0.54) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL20689050 0.81 TYK2 (0.47) CCNA2CDK2KDM4EALDH1A1HPGD
SCHEMBL20689557 0.81 KDM4E (0.36) CCNA2CDK2KDM4EALDH1A1HPGD
SCHEMBL20689269 0.80 TYK2 (0.55) CCNA2CDK2KDM4EALDH1A1HPGD
SCHEMBL20688925 0.77 TYK2 (0.48) TYK2
SCHEMBL20689559 0.76 TYK2 (0.59) KDM4ETYK2
SCHEMBL21285316 0.76 TYK2 (0.56) KDM4EALDH1A1HPGDHSD17B10NPC1
SCHEMBL20689444 0.76 TYK2 (0.52) TYK2
SCHEMBL20688924 0.75 KDM4E (0.44) CCNA2CDK2KDM4EALDH1A1HPGD
SCHEMBL21285337 0.74 KDM4E (0.46) CCNA2CDK2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 — — US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 — — US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
WO-2019023468-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2019-01-31 — — WO disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CCNA2 3267/4885CDK2 342/4885P2RX7 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback